| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Veterans Affairs Medical Center, Earle A. Chiles Research Institute, Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, OR, 97201;
Department of Microbiology, University of Los Angeles, CA 90024;
Department of Microbiology, University of Pennsylvania Medical School, Philadelphia, PA, 19104;
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115; and
¶ Cerus Corporation, Concord, CA 94520
The bacterium L. monocytogenes is a proposed vaccine carrier based upon the observation that this pathogen replicates within the intracytoplasmic environment facilitating delivery of Ag to the endogenous Ag processing and presentation pathway with subsequent stimulation of peptide specific MHC class I-restricted CD8+ effector cells. In this report, we evaluate virulence-attenuated strains of Listeria monocytogenes as vaccine vectors and examine whether existing antivector (antilisterial) immunity limits or alters its efficacy as a therapeutic cancer vaccine. Following immunization with virulence-attenuated mutants, we found that the effectiveness of L. monocytogenes as a recombinant cancer vaccine remains intact. In addition, we found that antibiotic treatment initiated 24 or 36 h following therapeutic immunization with recombinant L. monocytogenes allows full development of the antitumor response. We also demonstrate that the vaccine vector potential of L. monocytogenes is not limited in animals with existing antilisterial immunity. For these latter studies, mice previously immunized with wild-type L. monocytogenes were infused with melanoma cells and then 5 days later challenged with recombinant tumor Ag expressing L. monocytogenes. Collectively, these results add additional support for the use of L. monocytogenes as a vaccine vector and underscore its potential to be used repeatedly for stimulation of recall responses concomitant with primary cell-mediated responses to newly delivered heterologous tumor-associated epitopes.
This article has been cited by other articles:
|
|
 |
|
  M. L. Leong, J. Hampl, W. Liu, S. Mathur, K. S. Bahjat, W. Luckett, T. W. Dubensky Jr., and D. G. Brockstedt Impact of Preexisting Vector-Specific Immunity on Vaccine Potency: Characterization of Listeria monocytogenes-Specific Humoral and Cellular Immunity in Humans and Modeling Studies Using Recombinant Vaccines in Mice Infect. Immun., September 1, 2009; 77(9): 3958 - 3968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Maciag, M. M. Seavey, Z.-K. Pan, S. Ferrone, and Y. Paterson Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature Cancer Res., October 1, 2008; 68(19): 8066 - 8075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yan, J. Qiu, J. Chen, B. Ryan-Payseur, D. Huang, Y. Wang, L. Rong, J. A. Melton-Witt, N. E. Freitag, and Z. W. Chen Selected prfA* Mutations in Recombinant Attenuated Listeria monocytogenes Strains Augment Expression of Foreign Immunogens and Enhance Vaccine-Elicited Humoral and Cellular Immune Responses Infect. Immun., August 1, 2008; 76(8): 3439 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lauer, B. Hanson, E. E. Lemmens, W. Liu, W. S. Luckett, M. L. Leong, H. E. Allen, J. Skoble, K. S. Bahjat, N. E. Freitag, et al. Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains Infect. Immun., August 1, 2008; 76(8): 3742 - 3753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Smithey, S. Brandt, N. E. Freitag, D. E. Higgins, and H. G. A. Bouwer Stimulation of Enhanced CD8 T Cell Responses Following Immunization with a Hyper-Antigen Secreting Intracytosolic Bacterial Pathogen J. Immunol., March 1, 2008; 180(5): 3406 - 3416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Huang, J. Zhao, S. Shen, H. Li, K.-L. He, G.-X. Shen, L. Mayer, J. Unkeless, D. Li, Y. Yuan, et al. Listeria monocytogenes Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling Cancer Res., May 1, 2007; 67(9): 4346 - 4352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Orr, N. N. Orgun, C. B. Wilson, and S. S. Way Cutting Edge: Recombinant Listeria monocytogenes Expressing a Single Immune-Dominant Peptide Confers Protective Immunity to Herpes Simplex Virus-1 Infection J. Immunol., April 15, 2007; 178(8): 4731 - 4735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Kollmann, B. Reikie, D. Blimkie, S. S. Way, A. M. Hajjar, K. Arispe, A. Shaulov, and C. B. Wilson Induction of Protective Immunity to Listeria monocytogenes in Neonates J. Immunol., March 15, 2007; 178(6): 3695 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, X. Zhao, C. Zhou, B. Gu, and F. R. Frankel A truncated Bacillus subtilis dal gene with a 3' ssrA gene tag regulates the growth and virulence of racemase-deficient Listeria monocytogenes. Microbiology, October 1, 2006; 152(Pt 10): 3091 - 3102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhao, M. Zhang, Z. Li, and F. R. Frankel Vaginal Protection and Immunity after Oral Immunization of Mice with a Novel Vaccine Strain of Listeria monocytogenes Expressing Human Immunodeficiency Virus Type 1 gag. J. Virol., September 1, 2006; 80(18): 8880 - 8890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Roback Vaccine-Enhanced Donor Lymphocyte Infusion (veDLI) Hematology, January 1, 2006; 2006(1): 486 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Craft, K. W. Bruhn, B. D. Nguyen, R. Prins, J. W. Lin, L. M. Liau, and J. F. Miller The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine J. Immunol., August 1, 2005; 175(3): 1983 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Brockstedt, M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity PNAS, September 21, 2004; 101(38): 13832 - 13837. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
